ERBB2 and breast cancer: Lowenfeld et al. vaccinated ductal carcinoma in situ (DCIS) and early HER2-positive BC patients before breast surgery with HER2 peptide-pulsed DCV and showed 28% of pathological complete response (pCR) in DCIS (only 8.5% in BC), with immunogenic activity in the sentinel lymph nodes as well as in the systemic blood, with no adverse effects [56].